Posted by Michael Wonder on 24 Jun 2023
Pfizer and BioNTech submit applications to US FDA for Omicron XBB.1.5 adapted monovalent COVID-19 vaccine
23 June 2023 - The submissions reflect guidance from FDA and other major health authorities to provide COVID-19 vaccines better matched to currently circulating sub-lineages.
Pfizer and BioNTech today announced the companies have submitted regulatory applications to the US FDA for their Omicron XBB.1.5 adapted monovalent COVID-19 vaccine for individuals 6 months of age and older.
